

- Lambrolizumab, 103e-21
 LAMB syndrome. *See* Carney's syndrome/
 complex (LAMB/NAME syndrome)
 Lamellar bone, 2466
 Laminar-flow rooms, for neutropenic patients,
 492
 Laminectomy, for neck pain, 123
 Laminin, 462e-6
 Lamin proteins, 1554
 Lamivudine (3TC)
 adverse effects of, 380, 1274t, 2034
 for chronic HBV infection, 215e-4t, 215e-9,
 2034–2035, 2037t, 2038f, 2074
 for HBV prophylaxis in transplant recipient,
 927
 for HIV infection, 1274t, 1276–1277
 molecular structure of, 1273, 1276f
 resistance to, 215e-9, 1276, 1279f, 2034–2035,
 2040t, 2074
 Lamotrigine
 adverse effects of
 common, 2718t
 cutaneous, 381, 2552
 fever, 138
 hypersensitivity, 382. *See also* Drug-induced
 hypersensitivity syndrome (DIHS)
 neurologic, 2554t
 SJS or TEN, 383, 2718t. *See also* Stevens-
 Johnson syndrome (SJS); Toxic
 epidermal necrolysis (TEN)
 systemic, 2554t
 drug interactions of, 2554t
 for epilepsy, 2552, 2554t, 2556
 for mood disorders, 2718, 2718t
 overdose/poisoning with, 473e-10t
 pharmacology of, 2554t
 for SUNCT/SUNA prevention, 2596
 for trigeminal neuralgia, 2646
 LAMP2 deficiency (Danon's disease), 432e-4t,
 433e-5, 1566
 LAMP2 gene mutations, 1555t, 1566
 Lancinations, 158
 Langerhans cell histiocytosis (histiocytosis X),
 135e-9, 2257, 2264
 Langerhans cell sarcoma, 135e-9
 Language
 assessment of, 37e-1v, 177, 2537
 perisylvian network for, 177
 Language barriers, 16e-4
 Laninamivir, 215e-5
 Lanreotide
 for acromegaly, 2271
 adverse effects of, 567, 574
 for carcinoid syndrome, 567
 for gastrinoma, 2337
 for glucagonoma, 570
 for insulinoma, 569
 for NETs, 574
 structure of, 566f
 for VIPoma, 571
 Lansoprazole, 263, 1920, 1920t, 2337
 Lanthanum, 1816
 Laparoscopic adjustable gastric banding, 2398,
 2398f
 Laparoscopic adrenalectomy, 2319
 Laparoscopic sleeve gastrectomy, 2398, 2398f
 Laparoscopic Ventral Rectopexy (LVR), for rectal
 prolapse, 1974, 1975f
 Laparoscopy, 103e-3, 877–878
 Laparotomy, 1980
 Lapatinib
 action of, 102e-5t, 103e-19
 adverse effects of, 103e-26, 621
 for breast cancer, 102e-5t, 529
 genetic variations in response to, 39t
 in pregnancy, 124e-4
 Laplace's law, 265e-8
 LA-PTT, 406
 LARC/MIP-3a/Exodus-1, 372e-12t
 Large granular lymphocytes, 81e-2, 372e-1,
 372e-6. *See also* Natural killer (NK)
 cells
 Laron-type dwarfism, 94e-4, 375e-2
 Laropiprant, 96e-4
 Larva currens, 1415
 Larva migrans
 cutaneous
 clinical features of, 829, 1412
 diagnosis of, 245e-3t, 245e-5t
 pathogenesis of, 1412
 from pentastomes, 2747
 treatment of, 1411t
 ocular, 1411
 visceral
 clinical features of, 152e-6t, 1411
 diagnosis of, 152e-6t, 245e-3t, 245e-6t, 1411
 epidemiology of, 1411
 incubation period for, 152e-6t
 pathogenesis of, 1411
 in returning war veterans, 152e-6t
 treatment of, 152e-6t, 246e-8, 246e-9,
 1411–1412, 1411t
 Laryngeal cancer, 503. *See also* Head and neck
 cancer
 Laryngeal nerve palsy, 2649
 Laryngitis, 234
 Laryngotracheal stricture, 2203
 Laser iridectomy, 200
 Laser photocoagulation, 2424
 Laser therapy
 for basal cell carcinoma, 501
 for hair removal, 334
 for hemoptysis, 247
 for neck pain, 123
 for sea urchin spine removal, 2740
 for warts, 1201, 1201t
 LASIK, 195
 Lasofofifene, 531
 Lassa fever, 215e-6, 782–783, 1306t, 1320–1321
 Lassaviruses, 1304. *See also* Rabies
 Latency, 214e-7
 Latency-associated transcripts (LATs), of HSV,
 1175
 Latent tuberculosis infection (LTBI). *See*
 Tuberculosis (TB), latent infection
 Lateral epicondylitis, 2249
 Lateral femoral cutaneous neuropathy (meralgia
 paresthetica), 49, 463e-5, 463e-5f, 2692
 Lateral geniculate body, 195
 Lateral medullary stroke syndrome, 2576f, 2577
 Lateral sclerosis, 2632, 2659
 Latex agglutination assay, 150e-2, 888
 α -Latrotoxin, 2748
 LATs (latency-associated transcripts), of HSV,
 1175
 Laugier-Hunziker syndrome, 359
 Laurence-Moon-Biedl syndrome, 415e-5t
 Laurence-Moon syndrome, 2364
 Laxatives
 abuse of, 268, 270, 305, 307
 adverse effects of, 267, 269, 307
 for constipation, 61, 62t, 273, 274
 for internal radionuclide contamination,
 263e-6
 LCAT deficiency, familial, 2445
 LCK gene mutations, 101e-3t
 LCM (lymphocytic choriomeningitis), 891, 893,
 908t, 1306t, 1317–1318
 LCZ696, 1507
 LDH. *See* Lactate dehydrogenase (LDH)
 LDL. *See* Low-density lipoprotein (LDL)
 Lead oxide exposure, 472e-3
 Lead poisoning
 vs. ALS, 2633
 clinical features of, 472e-2t, 2607–2608
 diagnosis of, 472e-2t, 2689, 2766t
 hemolytic anemia in, 659
 hypertension and, 472e-1
 metabolism of, 472e-2t
 nephropathy in, 1856t, 1862
 neuropathy in, 2688t, 2689
 optic neuropathy in, 203
 oral manifestations of, 240t
 peripheral blood smear in, 81e-5f
 pregnancy-associated risks, 472e-1
 sources of, 472e-2t
 treatment of, 472e-2t, 2608
 Lead-time bias, 479, 509
 Leaky epithelia, 332e-3
 Leber's hereditary optic neuropathy (congenital
 amaurosis)
 clinical features of, 85e-5, 85e-6t, 202–203,
 1850t
 diagnosis of, 85e-5, 85e-6–7
 gene therapy for, 91e-3
 genetic considerations in, 202–203, 1850t
 genetic counseling in, 85e-9
 mitochondrial DNA mutation in, 85e-5,
 85e-6–7, 85e-6t
 treatment of, 206
 visual fields in, 197
 Leboombo virus, 1308t
 Lechiguanas virus, 1308t
 Lectins, 89e-1
 Ledipasvir, 2049
 Leech infestations, 2747
 Leflunomide
 adverse effects of, 2146t, 2687t
 for CMV infection, 922
 monitoring during treatment with, 2146t
 for psoriatic arthritis, 2177
 pyrimidine metabolism and, 431e-6
 for rheumatoid arthritis, 2145, 2146t
 for SLE, 2133
 Left bundle branch, 1471
 Left bundle branch block
 conditions associated with, 1454–1455
 ECG in, 269e-16f, 278e-9f, 1454, 1455f
 heart sounds in, 1447f
 Left coronary artery, anomalous origin of,
 1523
 Left ventricular aneurysm, 1610
 Left ventricular assist devices (LVADs)
 as bridge to cardiac transplantation, 1518
 components of, 1519f
 for heart failure, 1518
 for pulmonary edema, 1763
 results of, 1519
 types of, 1517–1518
 Left ventricular dysfunction
 cardiogenic shock in, 1759
 diagnosis of
 CMR, 270e-6–7, 270e-26v
 echocardiography, 270e-6–7, 270e-8f
 ventriculography, 1463–1464, 1464f
 in heart failure, 1502, 1502f. *See also* Heart
 failure (HF)
 in mitral regurgitation, 1543
 in myocardial infarction, 1607
 Left ventricular hypertrophy
 in chronic kidney disease, 1817
 ECG in, 269e-15f, 1454, 1454f
 hypertension and, 269e-15f, 1615
 with myocardial ischemia, 1579
 Left ventricular noncompaction, 1555t, 1564
 Left ventricular pressure-volume relationship,
 265e-10, 265e-10f
 Left ventricular remodeling, 1502–1503, 1503t,
 1607. *See also* Heart failure (HF)
 Left ventricular stroke work, 1748t
 Legal issues
 advance care planning, 58–59
 euthanasia and physician-assisted suicide,
 67–68
 incompetent patient, 17e-1–2
 mandated reporting, 17e-1
 Leg elevation, for stasis dermatitis/ulceration,
 346, 354t
 Legionella spp.
 adherence of, 145e-2t
 ecology of, 1014–1015
 genome of, 1016
 host response to, 1015–1016
 laboratory identification of, 150e-5t, 150e-8,
 1017, 1020t
 microbiology of, 1014
 Naegleria and, 1367
 serogroups of, 1014
 virulence of, 1016
 Legionella spp. infections, 1014
 in cancer patient, 489, 489t
 clinical features of, 1016